01 · Market Intelligence · Report type

KOL Mapping reports, across indications

A six-sheet KOL universe and engagement workbook, built gate by gate: sizing, tier classification, scientific influence, engagement readiness, MSL territory coverage, and cross-border network. Every KOL entry carries a verification tag.

KOL Mapping reports across indications

Breast Cancer HR+/HER2-
KOL
KOL Oncology Medical AffairsMedical Affairs

UK Breast Cancer HR+/HER2- KOL Mapping

A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Hereditary Angioedema
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Hereditary Angioedema KOL Mapping

KFSH&RC, AUH, and Hamad Medical Corporation anchor a GCC HAE specialist community that SACIA sizes at just 6-10 physicians regionwide. That concentration is exactly what this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
ATTR Amyloidosis
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK ATTR Amyloidosis KOL Mapping

The National Amyloidosis Centre holds the clinical-expert seat at every NICE ATTR appraisal to date. This workbook sizes the UK ATTR KOL network before a name enters it: NAC's 400-500-patient ATTRv surveillance registry, the separate UCL and Queen Elizabeth Hospital Birmingham National ATTRv Registry tracking approximately 800 patients, and the roughly 30 NHS centres running Tc-PYP scintigraphy nationally.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Dravet Syndrome
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Dravet Syndrome KOL Mapping

A five-institution Saudi consortium across Riyadh, Jeddah and Dammam tracked 44 Dravet patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
Sickle Cell Disease
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Sickle Cell Disease KOL Mapping

Four London teaching hospitals anchor roughly 6,000 of the UK's 15,000-17,000 sickle cell patients. Barts, King's, Imperial and Homerton, with Birmingham Heartlands, Manchester, Bristol and Nottingham forming the next ring. That eight-centre structure is exactly the institutional signal this workbook sizes before any individual name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Spinal Muscular Atrophy
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Spinal Muscular Atrophy KOL Mapping

Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Fabry Disease
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Fabry Disease KOL Mapping

KFSH&RC runs the only HEK293 amenable-mutation assay in the GCC. Its formulary committee recommendation drives NPHC coverage decisions for every Fabry disease treatment. That kind of single-institution gatekeeping is exactly the concentration this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
Myasthenia Gravis
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Myasthenia Gravis KOL Mapping

Just 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
Spinal Muscular Atrophy
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Spinal Muscular Atrophy KOL Mapping

Four designated GCC centres carry nearly all regional SMA gene-therapy and specialist referral activity. KAMC and KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi. This workbook sizes that institutional concentration before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
Pompe Disease
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Pompe Disease KOL Mapping

Six to eight named metabolic centres across the GCC hold ERT infusion capacity for Pompe disease. KFSH&RC leads with roughly 120 patients over 15 years. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
PNH
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK PNH KOL Mapping

Fewer than 25 consultants manage over 90% of the UK's PNH caseload. They sit across five NHS Highly Specialised Services centres anchored by the Leeds National PNH Service. That kind of institutional concentration is exactly the signal this workbook sizes before any individual name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Dravet Syndrome
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Dravet Syndrome KOL Mapping

Six NHS centres concentrate the UK's refractory Dravet syndrome cohort. Great Ormond Street, Bristol, Alder Hey, Birmingham Children's, Leeds and Newcastle. The British Paediatric Neurology Association's Dravet working group shapes NICE evidence review 18-24 months ahead of submission, and that institutional network is what this workbook sizes first, not a roster of named physicians.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Pompe Disease
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Pompe Disease KOL Mapping

A six-physician BIMDG subcommittee advises NICE directly on Pompe disease. It sits at the centre of a five-centre UK Pompe Consortium and an eight-centre NHS Highly Specialised Service network. That kind of institutional concentration is exactly what this workbook sizes before any individual name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
IgA Nephropathy
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK IgA Nephropathy KOL Mapping

The Renal Association's IgAN guideline committee, not any single physician, sets the reference point NICE checks against. This workbook sizes that committee and the network behind it before individual outreach begins.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Sickle Cell Disease
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC Sickle Cell Disease KOL Mapping

Only three GCC institutions run structured adult sickle cell programmes for 200,000-250,000 patients. KFSH&RC, KAMC and AUH. That three-centre concentration, anchored by the KFSH&RC Dammam flagship and 12+ MOH regional centres in Eastern Province, is exactly the institutional signal this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
PNH
KOL
KOL Rare Disease Medical AffairsMedical Affairs

FR PNH KOL Mapping

Saint-Louis Hospital anchors France's MaRIH-coordinated PNH reference network of 14 competence centres. Only 24 of the 50-plus centres in the national clone-observatory network actively report into it. That kind of institutional structure is exactly what this workbook sizes before any individual name enters it.

FR In-Market 24–32 pp PDF · Excel · PPT Read report →
Breast Cancer HR+/HER2-
KOL
KOL Oncology Medical AffairsMedical Affairs

US Breast Cancer HR+/HER2- KOL Mapping

A 9,146-patient US real-world study found no significant survival difference between palbociclib, ribociclib, and abemaciclib. When the drugs perform equivalently, KOL guidance decides which one gets prescribed, not clinical data.

US In-Market 24–32 pp PDF · Excel · PPT Read report →
Hereditary Angioedema
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Hereditary Angioedema KOL Mapping

Five NHS specialist centres manage more than 90% of UK HAE patients. Sheffield, Cambridge, Birmingham, Guy's and St Thomas', and Manchester. That concentration is what this workbook sizes before any physician enters the K1-K6 gate structure.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Fabry Disease
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Fabry Disease KOL Mapping

Royal Free London's National Fabry Service was NICE's appointed clinical expert twice over. It advised on both migalastat's HST4 and pegunigalsidase alfa's TA915, across a network of five named NHS lysosomal storage disorder centres. That repeated appointment is exactly the institutional signal this workbook sizes before any individual name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
Myasthenia Gravis
KOL
KOL Rare Disease Medical AffairsMedical Affairs

UK Myasthenia Gravis KOL Mapping

A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK carries UK myasthenia care. That network, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.

UK In-Market 24–32 pp PDF · Excel · PPT Read report →
ATTR Amyloidosis
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC ATTR Amyloidosis KOL Mapping

KFSH&RC maintains the only GCC-wide ATTRv genetic registry and houses the region's nuclear cardiology programme. Fewer than 8 named cardiology and scintigraphy centres region-wide, spanning KAMC, AUH, HMC Doha, and OCCI Muscat, define a small institutional field this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
IgA Nephropathy
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC IgA Nephropathy KOL Mapping

GCC IgA nephropathy expertise concentrates in five named tertiary centres. Roughly 300 practising nephrologists work the region, of whom 30 to 50 carry glomerular-disease subspecialty interest. This workbook sizes that concentrated institutional base before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →
PNH
KOL
KOL Rare Disease Medical AffairsMedical Affairs

GCC PNH KOL Mapping

Seven institutions across Riyadh, Jeddah, Dubai and Abu Dhabi hold the GCC's confirmed PNH caseload. Just 5 to 8 physicians function as genuine adoption gatekeepers. That kind of concentration is exactly what this workbook sizes before any individual name enters it.

GCC In-Market 24–32 pp PDF · Excel · PPT Read report →

KOL Mapping — frequently asked

What formats are included?

An editable 6-sheet Excel KOL workbook (Universe, Tier Scoring, Engagement Calendar, MSL Territory, Cross-Border Network, Evidence Register), a PDF summary brief, and a 45-minute analyst call.

How are KOL identities and rankings verified?

Every KOL entry is built from live PubMed, ClinicalTrials.gov, and guideline-authorship data, then tagged Verified / Industry benchmark / Requires client validation — no name ships unverified.

Can I scope this to a specific country or institution set?

Yes. You set the indication, geography, and institution scope; the workbook is built to your scope and delivered editable.